this post was submitted on 14 Jul 2026
20 points (88.5% liked)

World News

57078 readers
1120 users here now

A community for discussing events around the World

Rules:

Similarly, if you see posts along these lines, do not engage. Report them, block them, and live a happier life than they do. We see too many slapfights that boil down to "Mom! He's bugging me!" and "I'm not touching you!" Going forward, slapfights will result in removed comments and temp bans to cool off.

We ask that the users report any comment or post that violate the rules, to use critical thinking when reading, posting or commenting. Users that post off-topic spam, advocate violence, have multiple comments or posts removed, weaponize reports or violate the code of conduct will be banned.

All posts and comments will be reviewed on a case-by-case basis. This means that some content that violates the rules may be allowed, while other content that does not violate the rules may be removed. The moderators retain the right to remove any content and ban users.


Lemmy World Partners

News !news@lemmy.world

Politics !politics@lemmy.world

World Politics !globalpolitics@lemmy.world


Recommendations

For Firefox users, there is media bias / propaganda / fact check plugin.

https://addons.mozilla.org/en-US/firefox/addon/media-bias-fact-check/

founded 3 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] Jajcus@sh.itjust.works 1 points 1 day ago (1 children)

As I understand, this are just statistics useful for objectively comparing therapies. Median of 11 vs 7 months may be some measurable number of people who end cancer-free. But you cannot count people that will live a few decades more in a trial that last only some years.

[–] fullsquare@awful.systems 1 points 1 day ago* (last edited 1 day ago)

it's not even known yet and they say so:

The primary endpoint was progression free survival (PFS) assessed by BICR per RECIST 1.1. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DoR), and safety profile. (...) The OS data were immature.

it was also only for late stage metastatic patients with a very specific mutation. now, since AZ has the rights, and they have money for trials, they can try to get a trial for earlier stages, and so this new better drug might be used for larger patient population while still patented. and that would be money printer